Pharma BD Deal Intelligence
Sanofi's $4.8B all-cash acquisition of Ablynx gave it the first approved nanobody therapeutic platform in biotech, though no lead molecule, indication, or revenue figures are on record to confirm the platform delivered commercial returns.
Sanofi acquired Ablynx for $4.8B, a Belgian biotechnology firm.
Sanofi to acquire Ablynx for $4.8 billion, gaining a pipeline of more than 45 proprietary and partnered nanobody candidates across hematology, inflammation,…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Sanofi acquired Ablynx for $4.8B, a Belgian biotechnology firm.
2K US cases/yr · $1.5B Global TTP therapeutics
Acquired TTP is a life-threatening blood disorder caused by autoantibodies against ADAMTS13. Caplacizumab (Cablivi) was the first therapy specifically approved for aTTP, along with plasma exchange and immunosuppression.
Plasma exchange (cornerstone), corticosteroids, rituximab, caplacizumab (Cablivi, Sanofi/Ablynx). Key player: Sanofi (Cablivi, from Ablynx acquisition).
$5.0B Rare autoimmune therapeutics (nanobody-addressable)
Sanofi/Ablynx's Rare Autoimmune Diseases label spans multiple Nanobody programs: caplacizumab (Cablivi, FDA-approved 2019 for aTTP, ~$300M sales), vobarilizumab (IL-6R; failed Phase 2 SLE/RA, discontinued), ozoralizumab (TNF, approved in Japan for RA as Nanozora). Competitive context is indication-specific: aTTP — PEX+rituximab+immunosuppression; SLE — Benlysta (belimumab, GSK), Saphnelo (anifrolumab, AZ). Aggregate 'Rare Autoimmune Diseases' label should be split into specific conditions for per-indication landscapes.
Sanofi completed $4.8B acquisition of Ablynx, gaining the nanobody technology platform and lead asset caplacizumab for rare blood disorders.
FDA approved Cablivi for acquired thrombotic thrombocytopenic purpura, making it the world's first approved nanobody-based drug and validating the Ablynx platform.
Ablynx nanobody technology integrated into Sanofi R&D, powering multiple pipeline candidates. Cablivi trending toward $500M peak annual sales globally.
Delivered both a commercial product (Cablivi) and a transformative technology platform. Nanobody tech now underpins multiple Sanofi programs. Clear strategic win.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Ablynx NV (this deal) | 2018 | $4.8B | 67 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2018 deals · Sanofi SA deals · Immunology deals